MarketPulse
A

$ARGX

6 articles found
5 positive
0 negative
1 neutral
The Motley FoolThe Motley Fool··Jonathan Ponciano

RTW Investments Bets $193M on Apellis Rebound Despite 29% Stock Decline

RTW Investments establishes $193M position in Apellis Pharmaceuticals despite 29% stock decline, betting on turnaround potential of $689M revenue-generating biotech.
ARGXAPLSMDGLINSMinstitutional investmentbiotech investment
GlobeNewswire Inc.GlobeNewswire Inc.··Unknown

Unnatural Products Lands $45M Series B, Novartis Deal Worth $1.7B

Biotech startup Unnatural Products secures $45M Series B funding led by The Venture Collective and inks $1.7B milestone deal with Novartis for oral peptide therapeutics.
MRKARGXNVSmacrocyclic peptidesSeries B funding
GlobeNewswire Inc.GlobeNewswire Inc.··Researchandmarkets.Com

Argenx's Vyvgart Poised for Explosive Growth as Autoimmune Market Expands

Argenx's Vyvgart gains momentum with Japan approval and Fujifilm partnership, positioning the FcRn inhibitor for significant market expansion across multiple autoimmune indications through 2030.
ARGXFUJIYVYVGARTbiologic therapy
GlobeNewswire Inc.GlobeNewswire Inc.··American Kidney Fund

American Kidney Fund Launches National Awareness Campaign Amid Rising Disease Prevalence

American Kidney Fund launches "Kidneys Count" campaign March 1, 2026, promoting early detection and prevention of kidney disease affecting 1 in 7 American adults.
AMGNARGXNVSTVTXkidney diseaseearly detection
BenzingaBenzinga··Vandana Singh

Argenx Reports Phase 3 Success for VYVGART in Ocular Myasthenia Gravis

Argenx's VYVGART achieves Phase 3 success for ocular myasthenia gravis, meeting primary endpoint. Company plans FDA application to expand indication for the rare eye disorder treatment.
ARGXPhase 3 clinical trialFDA approval
GlobeNewswire Inc.GlobeNewswire Inc.··Argenx Se

argenx's VYVGART Meets Primary Endpoint in Ocular Myasthenia Gravis Trial

argenx's VYVGART met its primary endpoint in a Phase 3 ocular myasthenia gravis trial, showing significant symptom improvements. The company plans FDA approval for label expansion.
ARGXFDA approvalPhase 3 trial